AIRLINK 197.47 Decreased By ▼ -0.50 (-0.25%)
BOP 9.98 Decreased By ▼ -0.06 (-0.6%)
CNERGY 7.27 Decreased By ▼ -0.02 (-0.27%)
FCCL 36.50 Increased By ▲ 0.50 (1.39%)
FFL 16.74 Decreased By ▼ -0.17 (-1.01%)
FLYNG 25.65 Increased By ▲ 0.61 (2.44%)
HUBC 135.20 Increased By ▲ 1.17 (0.87%)
HUMNL 14.02 Decreased By ▼ -0.12 (-0.85%)
KEL 4.79 Increased By ▲ 0.01 (0.21%)
KOSM 6.90 Decreased By ▼ -0.04 (-0.58%)
MLCF 45.40 Increased By ▲ 0.42 (0.93%)
OGDC 217.50 Decreased By ▼ -0.73 (-0.33%)
PACE 6.95 Increased By ▲ 0.01 (0.14%)
PAEL 41.17 Decreased By ▼ -0.25 (-0.6%)
PIAHCLA 16.71 Decreased By ▼ -0.15 (-0.89%)
PIBTL 8.46 No Change ▼ 0.00 (0%)
POWER 9.36 Decreased By ▼ -0.03 (-0.32%)
PPL 182.90 Decreased By ▼ -3.03 (-1.63%)
PRL 41.05 Decreased By ▼ -0.22 (-0.53%)
PTC 24.80 Increased By ▲ 0.03 (0.12%)
SEARL 104.24 Decreased By ▼ -0.41 (-0.39%)
SILK 1.01 No Change ▼ 0.00 (0%)
SSGC 40.72 Decreased By ▼ -0.19 (-0.46%)
SYM 17.86 Decreased By ▼ -0.19 (-1.05%)
TELE 8.89 Decreased By ▼ -0.02 (-0.22%)
TPLP 12.67 Decreased By ▼ -0.17 (-1.32%)
TRG 66.49 Decreased By ▼ -0.11 (-0.17%)
WAVESAPP 11.20 Decreased By ▼ -0.10 (-0.88%)
WTL 1.76 Decreased By ▼ -0.02 (-1.12%)
YOUW 3.90 Decreased By ▼ -0.10 (-2.5%)
BR100 12,075 Decreased By -34 (-0.28%)
BR30 36,457 Decreased By -140.4 (-0.38%)
KSE100 114,763 Decreased By -279 (-0.24%)
KSE30 36,094 Decreased By -105.7 (-0.29%)
World

White House considering intellectual property waiver for COVID-19 vaccines

  • Tai discussed the issue on Monday with drugmakers Pfizer and AstraZeneca PLC, noting her interest in a solution that gave developing countries a role in addressing critical gaps in vaccine production and distribution.
Published April 28, 2021

WASHINGTON: The White House is considering options for maximizing global production and supply of COVID-19 vaccines at the lowest cost, including backing a proposed waiver of intellectual property rights, but no decision has been made, press secretary Jen Psaki said on Tuesday.

"There are a lot of different ways to do that. Right now, that's one of the ways, but we have to assess what makes the most sense," Psaki said, adding that US officials were studying whether it would be more effective to boost existing manufacturing of the vaccines in the United States.

US Trade Representative Katherine Tai had not made a recommendation on the issue, and President Joe Biden had not made a decision, she said.

US lawmakers and nonprofit groups are heaping pressure on the Biden administration to back the temporary patent waiver to help poor countries contain the pandemic as India and other countries battle a massive surge in cases.

The United States and several other countries have thus far blocked negotiations at the World Trade Organization (WTO) about a proposal led by India and South Africa that would waive the IP rights of pharmaceutical companies to allow developing countries to produce COVID-19 vaccines.

Proponents are pushing Washington to change course ahead of another WTO meeting on the issue on April 30.

Critics say waiving the WTO's agreement on Trade-Related Aspects of Intellectual Property could reduce the safety of vaccines, and that setting up production in new places would sap resources needed to boost production in existing locations.

Tai discussed the issue on Monday with drugmakers Pfizer and AstraZeneca PLC, noting her interest in a solution that gave developing countries a role in addressing critical gaps in vaccine production and distribution.

US industry executives believe Tai may be leaning toward backing the waiver after she called the gaping divide between developed and developing countries' access to medicines "completely unacceptable" and said industry needed to make sacrifices in times of crisis.

Comments

Comments are closed.